DISC1 and psychiatric disorder: This approach, which targets the receptor–receptor interaction instead of the receptors alone, has already been successful with the dopamine D2R and DISC1 (disrupted in schizophrenia1), a scaffolding protein involved in psychiatric diseases [39].